Organization
Turning Point Therapeutics
9 clinical trials
1 abstract
Clinical trial
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Status: Recruiting, Estimated PCD: 2028-02-29
Clinical trial
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-01-04
Clinical trial
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)Status: Terminated, Estimated PCD: 2023-03-01
Clinical trial
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 RearrangementsStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 AlterationsStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLCStatus: Terminated, Estimated PCD: 2023-04-18
Clinical trial
A Phase 1/2 of Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects With Locally Advanced or Metastatic NSCLC, Gastric Cancer, or Solid Tumors Harboring Genetic Alterations in METStatus: Active (not recruiting), Estimated PCD: 2025-03-02
Clinical trial
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or MutationsStatus: Terminated, Estimated PCD: 2023-05-22
Clinical trial
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsStatus: Withdrawn, Estimated PCD: 2025-08-31
Abstract
MANCAN2: A multicentre randomised controlled trial of self-help cognitive behavioural therapy (CBT) to manage hot flush and night sweats (HFNS) symptoms in patients with prostate cancer receiving androgen deprivation therapy (ADT).Org: Southampton Clinical Trials Unit, University of Southampton, University Hospital Southampton NHS Foundation Trust, Turning Point Therapeutics, Guys and St Thomas NHS Foundation Trust,